CVS Health Reports Q4 Beat but Maintains Full-Year Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2026
0mins
Should l Buy CVS?
Source: seekingalpha
- Strong Earnings Performance: CVS Health's Q4 2025 revenue grew approximately 8% year-over-year to $105.7 billion, exceeding market expectations by $2.1 billion, although adjusted EPS fell about 8% to $1.09, still beating forecasts by $0.09, indicating robust overall business performance.
- Growth in Health Insurance Segment: Revenue from CVS's Health Care Benefits segment rose about 10% year-over-year to $36.3 billion, with a medical benefit ratio steady at 94.8%, reflecting improvements in government health plans and demonstrating the company's sustained competitiveness in the health insurance market.
- Pharmacy & Consumer Wellness Growth: This segment recorded $37.7 billion in revenue during the period, indicating approximately 12% year-over-year growth, with prescriptions filled increasing by 6.3% on a 30-day equivalent basis, showcasing strong consumer demand that further propelled overall revenue growth.
- Declining Profitability: Despite CVS's diluted EPS rising approximately 77% year-over-year to $2.30, primarily due to a $1.9 billion tax benefit, its gross margin fell by 50 basis points to 5.2%, indicating challenges in cost control, necessitating attention to the recovery of profitability in the future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVS
Wall Street analysts forecast CVS stock price to rise
17 Analyst Rating
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 72.490
Low
91.00
Averages
96.71
High
105.00
Current: 72.490
Low
91.00
Averages
96.71
High
105.00
About CVS
CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. The Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and, through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Five-Year Investment Analysis of CVS Health
- Investment Return Comparison: Investing $100 in CVS Health five years ago would yield approximately $108.11 today, reflecting a mere 1.6% annual growth rate, significantly lagging behind the S&P 500's 11% growth, indicating CVS's limited investment appeal.
- Revenue Growth Performance: CVS reported an 8.2% year-over-year revenue growth in Q4, with a full-year growth of 7.8%, but rising costs and shrinking profit margins pose challenges that could hinder future performance.
- Dividend Yield Analysis: With a dividend yield of 3.8%, CVS provides a stable income source; however, compared to faster-growing companies, its attractiveness may be limited, prompting investors to consider alternatives carefully.
- Market Competition Pressure: Despite CVS's established position in healthcare, analysts highlight the presence of more promising investment options, as CVS did not make the Motley Fool's list of the top 10 stocks, reflecting its relative disadvantage.
See More
CVS Health Faces Profit Pressure Amid Rising Costs
- Stock Performance: CVS Health's stock has only appreciated about 8.11% over the past five years, translating to an average annual growth rate of 1.6%, which significantly lags behind the S&P 500's 11% growth, indicating a lack of competitive strength in the market.
- Weak Revenue Growth: While CVS posted an 8.2% year-over-year growth in Q4 and 7.8% for the full year, the lack of significant rate increases in Medicare Advantage plans may limit future growth potential, potentially undermining investor confidence.
- Profit Margin Pressure: The company is facing rising cost pressures that are further squeezing its already thin profit margins, which could adversely affect its long-term profitability and shareholder returns.
- Dividend Appeal: Although CVS Health offers a dividend yield of 3.8%, which attracts some investors, there are faster-growing companies and higher-yielding dividend stocks in the market, prompting investors to carefully consider their portfolio choices.
See More
Investment Return Analysis of CVS Health
- Investment Return Comparison: Investing $100 in CVS Health five years ago would yield approximately $108.11 today, reflecting a mere 1.6% average annual growth, significantly trailing the S&P 500's 11% average, indicating CVS's underperformance relative to the broader market.
- Revenue Growth Performance: CVS reported an 8.2% year-over-year revenue growth in Q4 and a 7.8% full-year growth, showcasing substantial growth; however, the company faces challenges in maintaining profit margins, highlighting the difficulty in balancing growth and profitability.
- Market Challenges: CVS's Aetna business plays a crucial role in Medicare Advantage plans, yet these plans are not expected to see significant rate increases this year, potentially impacting future revenue growth and reflecting competitive pressures in the market.
- Dividend Yield Analysis: With a current dividend yield of 3.8%, CVS offers a stable income source; however, investors should be aware of faster-growing companies and higher-yielding dividend stocks available in the market, necessitating careful selection to optimize their portfolios.
See More
Healthcare Stocks Performance in Economic Recession
- Defensive Healthcare Advantage: Large-cap healthcare stocks like Johnson & Johnson and CVS Health exhibit strong performance during economic downturns, with low beta values (0.33 for JNJ and 0.46 for CVS) indicating smaller losses during market declines, thus providing a stable income source for risk-averse investors.
- Rising Recession Risks: The ongoing conflict in Iran has led to soaring energy and food prices, increasing the risk of a global economic recession, prompting investors to gravitate towards healthcare stocks to mitigate potential market volatility and uncertainty.
- High-Risk, High-Reward Strategy: Smaller healthcare companies such as Grail and Viking Therapeutics present high-risk, high-reward investment opportunities; despite Grail's multi-cancer early detection test failing to meet primary endpoints, follow-up data could potentially shift market perceptions positively.
- Portfolio Diversification: In light of increasing economic uncertainty, building a diversified portfolio of small healthcare companies can effectively mitigate stock-specific risks, particularly those reliant on clinical trial outcomes, which may offer potential returns amidst market fluctuations.
See More
Iran Conflict Raises Recession Risks Amid Inflation
- Recession Risk: The ongoing conflict in Iran is causing inflationary pressures from soaring energy and food prices, complicating global economic challenges and increasing investor interest in healthcare stocks as a defensive measure.
- Defensive Healthcare Stocks: Large-cap pharmaceutical company Johnson & Johnson (JNJ) and integrated healthcare company CVS Health are viewed as defensive stocks, with JNJ's beta at 0.33 and CVS at 0.46, indicating their relative stability during economic downturns.
- Opportunities in Small-Cap Stocks: Investors may consider small- and mid-cap healthcare companies whose growth relies on binary events like clinical trial results, as successful firms can offset losses from others, despite the inherent risks.
- Investment Strategy Choices: Risk-averse investors may prefer low-beta defensive stocks, while risk-seeking investors might opt for high-risk, high-reward healthcare stocks to navigate potential recessionary pressures.
See More
U.S. Adds 178K Jobs in March, Unemployment Rate Dips to 4.3%
- Labor Market Recovery: The U.S. added 178,000 nonfarm jobs in March, significantly surpassing the Dow Jones estimate of 59,000, indicating signs of economic recovery despite the persistent slow-growth trend.
- Sector Growth Highlights: The healthcare sector was the largest contributor, adding 76,000 jobs, with 54,000 coming from returning workers post-strike, suggesting a rebound in this sector after facing short-term challenges.
- Unemployment Rate Changes: Although the unemployment rate dipped slightly to 4.3%, the labor force participation rate fell to 61.9% due to a decline of 396,000 individuals, reflecting underlying pressures in the job market.
- Wage Growth Slowdown: Average hourly earnings rose by only 0.2% in March, with a year-over-year increase of 3.5%, both below expectations, indicating that sluggish wage growth may impact consumer spending and overall economic growth.
See More
Five-Year Investment Analysis of CVS Health
- Investment Return Comparison: Investing $100 in CVS Health five years ago would yield approximately $108.11 today, reflecting a mere 1.6% annual growth rate, significantly lagging behind the S&P 500's 11% growth, indicating CVS's limited investment appeal.
- Revenue Growth Performance: CVS reported an 8.2% year-over-year revenue growth in Q4, with a full-year growth of 7.8%, but rising costs and shrinking profit margins pose challenges that could hinder future performance.
- Dividend Yield Analysis: With a dividend yield of 3.8%, CVS provides a stable income source; however, compared to faster-growing companies, its attractiveness may be limited, prompting investors to consider alternatives carefully.
- Market Competition Pressure: Despite CVS's established position in healthcare, analysts highlight the presence of more promising investment options, as CVS did not make the Motley Fool's list of the top 10 stocks, reflecting its relative disadvantage.
See More
CVS Health Faces Profit Pressure Amid Rising Costs
- Stock Performance: CVS Health's stock has only appreciated about 8.11% over the past five years, translating to an average annual growth rate of 1.6%, which significantly lags behind the S&P 500's 11% growth, indicating a lack of competitive strength in the market.
- Weak Revenue Growth: While CVS posted an 8.2% year-over-year growth in Q4 and 7.8% for the full year, the lack of significant rate increases in Medicare Advantage plans may limit future growth potential, potentially undermining investor confidence.
- Profit Margin Pressure: The company is facing rising cost pressures that are further squeezing its already thin profit margins, which could adversely affect its long-term profitability and shareholder returns.
- Dividend Appeal: Although CVS Health offers a dividend yield of 3.8%, which attracts some investors, there are faster-growing companies and higher-yielding dividend stocks in the market, prompting investors to carefully consider their portfolio choices.
See More
Investment Return Analysis of CVS Health
- Investment Return Comparison: Investing $100 in CVS Health five years ago would yield approximately $108.11 today, reflecting a mere 1.6% average annual growth, significantly trailing the S&P 500's 11% average, indicating CVS's underperformance relative to the broader market.
- Revenue Growth Performance: CVS reported an 8.2% year-over-year revenue growth in Q4 and a 7.8% full-year growth, showcasing substantial growth; however, the company faces challenges in maintaining profit margins, highlighting the difficulty in balancing growth and profitability.
- Market Challenges: CVS's Aetna business plays a crucial role in Medicare Advantage plans, yet these plans are not expected to see significant rate increases this year, potentially impacting future revenue growth and reflecting competitive pressures in the market.
- Dividend Yield Analysis: With a current dividend yield of 3.8%, CVS offers a stable income source; however, investors should be aware of faster-growing companies and higher-yielding dividend stocks available in the market, necessitating careful selection to optimize their portfolios.
See More
Healthcare Stocks Performance in Economic Recession
- Defensive Healthcare Advantage: Large-cap healthcare stocks like Johnson & Johnson and CVS Health exhibit strong performance during economic downturns, with low beta values (0.33 for JNJ and 0.46 for CVS) indicating smaller losses during market declines, thus providing a stable income source for risk-averse investors.
- Rising Recession Risks: The ongoing conflict in Iran has led to soaring energy and food prices, increasing the risk of a global economic recession, prompting investors to gravitate towards healthcare stocks to mitigate potential market volatility and uncertainty.
- High-Risk, High-Reward Strategy: Smaller healthcare companies such as Grail and Viking Therapeutics present high-risk, high-reward investment opportunities; despite Grail's multi-cancer early detection test failing to meet primary endpoints, follow-up data could potentially shift market perceptions positively.
- Portfolio Diversification: In light of increasing economic uncertainty, building a diversified portfolio of small healthcare companies can effectively mitigate stock-specific risks, particularly those reliant on clinical trial outcomes, which may offer potential returns amidst market fluctuations.
See More
Iran Conflict Raises Recession Risks Amid Inflation
- Recession Risk: The ongoing conflict in Iran is causing inflationary pressures from soaring energy and food prices, complicating global economic challenges and increasing investor interest in healthcare stocks as a defensive measure.
- Defensive Healthcare Stocks: Large-cap pharmaceutical company Johnson & Johnson (JNJ) and integrated healthcare company CVS Health are viewed as defensive stocks, with JNJ's beta at 0.33 and CVS at 0.46, indicating their relative stability during economic downturns.
- Opportunities in Small-Cap Stocks: Investors may consider small- and mid-cap healthcare companies whose growth relies on binary events like clinical trial results, as successful firms can offset losses from others, despite the inherent risks.
- Investment Strategy Choices: Risk-averse investors may prefer low-beta defensive stocks, while risk-seeking investors might opt for high-risk, high-reward healthcare stocks to navigate potential recessionary pressures.
See More
U.S. Adds 178K Jobs in March, Unemployment Rate Dips to 4.3%
- Labor Market Recovery: The U.S. added 178,000 nonfarm jobs in March, significantly surpassing the Dow Jones estimate of 59,000, indicating signs of economic recovery despite the persistent slow-growth trend.
- Sector Growth Highlights: The healthcare sector was the largest contributor, adding 76,000 jobs, with 54,000 coming from returning workers post-strike, suggesting a rebound in this sector after facing short-term challenges.
- Unemployment Rate Changes: Although the unemployment rate dipped slightly to 4.3%, the labor force participation rate fell to 61.9% due to a decline of 396,000 individuals, reflecting underlying pressures in the job market.
- Wage Growth Slowdown: Average hourly earnings rose by only 0.2% in March, with a year-over-year increase of 3.5%, both below expectations, indicating that sluggish wage growth may impact consumer spending and overall economic growth.
See More
